Insurance barriers, Medicare exclusions, and prior-authorization requirements are preventing many Americans from accessing GLP-1 weight-loss drugs despite stabilized supply and high demand.
Government shutdown impacts senior access to services
Medicare's refusal to reimburse some telehealth visits and USDA funding shortfalls risk forcing costly in-person care and lapsing SNAP benefits for millions.